Great Point Partners LLC Rigel Pharmaceuticals Inc Transaction History

Great Point Partners LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.67 - $3.19 $2.68 Million - $12.8 Million	-4,000,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.22 - $3.45 $2.22 Million - $3.45 Million	-1,000,000 Reduced 20.0%	4,000,000 $12 Million
Q4 2021 Feb 14, 2022	BUY	$2.36 - $3.57 $7.13 Million - $10.8 Million	3,020,000 Added 152.53%	5,000,000 $13.3 Million
Q3 2021 Nov 15, 2021	BUY	$3.5 - $4.5 $1.68 Million - $2.16 Million	480,000 Added 32.0%	1,980,000 $7.19 Million
Q2 2021 Aug 16, 2021	BUY	$3.09 - $4.54 $4.64 Million - $6.81 Million	1,500,000 New	1,500,000 $6.51 Million
Q3 2018 Nov 14, 2018	SELL	$2.6 - $3.59 $8.86 Million - $12.2 Million	-3,407,840 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$2.83 - $4.11 $14.6 Million - $21.3 Million	-5,171,614 Reduced 60.28%	3,407,840 $9.64 Million
Q1 2018 May 14, 2018	BUY	$3.54 - $4.54 $2.45 Million - $3.14 Million	690,873 Added 8.76%	8,579,454 $0
Q4 2017 Feb 14, 2018	SELL	$3.23 - $4.3 $3.93 Million - $5.23 Million	-1,217,110 Reduced 13.37%	7,888,581 $30.6 Million
Q3 2017 Nov 14, 2017	BUY	$2.18 - $2.57 $19.9 Million - $23.4 Million	9,105,691	9,105,691 $23.1 Million

335K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $3.78B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Great Point Partners LLC with notifications on news.